1.A Case of Diffuse Large B Cell Lymphoma in Middle Ear Cavity
Yong Jae SONG ; Jungho HA ; Se Hyun YEOU ; Jeong Hun JANG
Korean Journal of Otolaryngology - Head and Neck Surgery 2024;67(2):107-112
Diffuse large B cell lymphoma (DLBCL), being one of the major subtypes of non-Hodgikin’s lymphoma, is marked by extranodal involvement. In patients with DLBCL, the stomach and gastrointestinal tract are commonly involved, but few cases have reported the involvement with the middle ear cavity and temporal bone. The present study reports a patient diagnosed with DLBCL characterized by middle ear cavity involvement. We also reviewed other similar cases in the literature.
2.Morphologic Analysis of Pulmonary Neuroendocrine Tumors.
Seung Seok LEE ; Myunghee KANG ; Seung Yeon HA ; Jungsuk AN ; Mee Sook ROH ; Chang Won HA ; Jungho HAN
Korean Journal of Pathology 2013;47(1):16-20
BACKGROUND: Few studies on how to diagnose pulmonary neuroendocrine tumors through morphometric analysis have been reported. In this study, we measured and analyzed the characteristic parameters of pulmonary neuroendocrine tumors using an image analyzer to aid in diagnosis. METHODS: Sixteen cases of typical carcinoid tumor, 5 cases of atypical carcinoid tumor, 15 cases of small cell carcinoma, and 51 cases of large cell neuroendocrine carcinoma were analyzed. Using an image analyzer, we measured the nuclear area, perimeter, and the major and minor axes. RESULTS: The mean nuclear area was 0.318+/-0.101 microm2 in typical carcinoid tumors, 0.326+/-0.119 microm2 in atypical carcinoid tumors, 0.314+/-0.107 microm2 in small cell carcinomas, and 0.446+/-0.145 microm2 in large cell neuroendocrine carcinomas. The mean nuclear circumference was 2.268+/-0.600 microm in typical carcinoid tumors, 2.408+/-0.680 microm in atypical carcinoid tumors, 2.158+/-0.438 microm in small cell carcinomas, and 3.247+/-1.276 microm in large cell neuroendocrine carcinomas. All parameters were useful in distinguishing large cell neuroendocrine carcinoma from other tumors (p=0.001) and in particular, nuclear circumference was the most effective (p=0.001). CONCLUSIONS: Pulmonary neuroendocrine tumors showed nuclear morphology differences by subtype. Therefore, evaluation of quantitative nuclear parameters improves the accuracy and reliability of diagnosis.
Carcinoid Tumor
;
Carcinoma, Large Cell
;
Carcinoma, Neuroendocrine
;
Carcinoma, Small Cell
;
Neuroendocrine Tumors
3.Dementia Pugilistica with Clinical Features of Frontotemporal Dementia and Parkinsonism: Case Report.
Youngsoon YANG ; Jaejeong JOO ; Jinho KANG ; Sangwo HAN ; Sangwon HA ; Jungho HAN ; Eunkyung CHO ; Dooeung KIM
Dementia and Neurocognitive Disorders 2013;12(3):78-80
Dementia pugilistica (DP) or chronic traumatic encephalopathy (CTE) is a neurodegenerative disease or dementia that may affect amateur or professional boxers as well as athletes in other sports who suffer concussions. The condition is thought to affect around 15% to 20% of professional boxers and caused by repeated concussive or subconcussive blows. CTE was in the past referred to as dementia pugilistica, which reflected the prevailing notion that this condition was restricted to boxers. Recent research, however, has demonstrated neuropathological evidence of CTE in retired American football players, a professional wrestler, a professional hockey player and a soccer player, as well as in nonathletes. It is probable that many individuals are susceptible to CTE, including those who experience falls, motor vehicle accidents, assaults, epileptic seizures, or military combat, and that repeated mild closed head trauma of diverse origin is capable of instigating the neurodegenerative cascade leading to CTE. We report a 62-year old man suspicious of dementia pugilistica with clinical features of frontotemporal dementia and parkinsonism.
Athletes
;
Brain Injury, Chronic
;
Dementia
;
Epilepsy
;
Football
;
Frontotemporal Dementia
;
Head Injuries, Closed
;
Hockey
;
Humans
;
Military Personnel
;
Motor Vehicles
;
Neurodegenerative Diseases
;
Parkinsonian Disorders
;
Soccer
;
Sports
4.Improved Bone Conduction Hearing After Middle Ear Surgery: Investigation of the Improvement Mechanism
Hantai KIM ; Jungho HA ; Ga Young GU ; Yun-Hoon CHOUNG
Clinical and Experimental Otorhinolaryngology 2023;16(1):20-27
Objectives:
. When performing middle ear operations, such as ossiculoplasty or stapes surgery, patients and surgeons expect an improvement in air conduction (AC) hearing, but generally not in bone conduction (BC). However, BC improvement has often been observed after surgery, and the present study investigated this phenomenon.
Methods:
. We reviewed the preoperative and postoperative surgical outcomes of 583 patients who underwent middle ear surgery. BC improvement was defined as a BC threshold decrease of >15 dB at two or more frequencies. Subjects in group A underwent staged ossiculoplasty after canal wall up mastoidectomy (CWUM), group B underwent staged ossiculoplasty after canal wall down mastoidectomy (CWDM), group C underwent ossiculoplasty only (thus, they had no prior history of CWUM or CWDM), and group D received stapes surgery. We created a hypothetical circuit model to explain this phenomenon.
Results:
. BC improvement was detected in 12.8% of group A, 9.1% of group B, and 8.5% of group C. The improvement was more pronounced in group D (27.0%). A larger gain in AC hearing was weakly correlated with greater BC improvement (Pearson’s r=0.395 in group A, P<0.001; r=0.375 in group B, P<0.001; r=0.296 in group C, P<0.001; r=0.422 in group D, P=0.009). Notably, patients with otosclerosis even experienced postoperative BC improvements as large as 10.0 dB, from a mean value of 30.3 dB (standard error [SE], 3.2) preoperatively to 20.3 dB (SE, 3.2) postoperatively, at 1,000 Hz, as well as an improvement of 9.2 dB at 2,000 Hz, from 37.8 dB (SE, 2.6) to 28.6 dB (SE, 3.1).
Conclusion
. BC improvement may be explained by a hypothetical circuit model applying the third window theory. Surgeons should keep in mind the possibility of BC improvement when making a management plan.
5.Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (hTERT).
Eunhee KIM ; Joo Hang KIM ; Ha Youn SHIN ; Han Saem LEE ; Joo Hyuk SOHN ; Jai Myung YANG ; Jungho KIM ; Chae Ok YUN
Cancer Research and Treatment 2003;35(3):191-206
PURPOSE: This study has been planned to generate a replication-competent adenovirus which replicates in a cancer cell-specific manner, thus minimizing the side effects and toxicity of cancer gene therapy. MATERIALS AND METHODS: we have generated an E1B 19 kD attenuated recombinant adenoviruses, Ad-TERT-delta19 and Ad-mTERT-delta19, which encode E1A gene driven by the wild type hTERT and modified m-hTERT promoter containing additional c-myc and Sp1 binding sites in the backbone of Ad-deltaE1B19. The in vitro efficacy and specificity of the hTERT and m-hTERT promoter have been evaluated by the comparison of viral replication and cytopathic effect in cancer cells and normal cell lines. To assess anti-tumor effect and safety of hTERT or m-hTERT promoter driven replication competent adenoviruses, tumor regression after subcutaneous injection in subcutaneous C33A xenografts and lacZ expression after systemic injection in organs were examined. RESULTS: The activation of hTERT or m-hTERT promoter was significantly up-regulated only in hTERT-positive cells, but not in hTERT-negative cells. Moreover, the activity of m-hTERT promoter was substantially increased in hTERT-positive cancer cells, but not in hTERT-negative cells. While Ad-TERT-delta19 replicated in and induced cytopathic effect in cancer and in some normal cell lines, Ad-mTERT-delta19 enhanced viral replication and cytopathic effect in cancer cells only. Furthermore, the growth of established human cervical carcinoma in nude mice was significantly suppressed by intratumoral injection of Ad-mTERT-delta19. CONCLUSIONS: The use of m-hTERT promoter is not only useful in the regulation of therapeutic gene expression but also that replication-competent oncolytic adenovirus under the control of m-hTERT promoter may be a new promising tool for the treatment of human malignancies.
Adenoviridae*
;
Animals
;
Binding Sites
;
Cell Line
;
Gene Expression
;
Genes, Neoplasm
;
Heterografts
;
Humans*
;
Injections, Subcutaneous
;
Mice
;
Mice, Nude
;
Sensitivity and Specificity
;
Telomerase*